Biotech firms award new hires stock options, some worth hundreds of thousands

Biotech and pharmaceutical firms Crowned inducement equity awards for new hires under Nasdaq Rule 5635(c)(4), including X4 Pharmaceuticals, Aura Biosciences, Akebia Therapeutics, Abeona Therapeutics, and Faeth Therapeutics. The awards typically combine stock options and restricted stock units with exercise prices set to the grant date closing price and vesting schedules that advance 25% after one year and the remainder in monthly installments over three years, contingent on continued employment. X4 issued 50,000 options; Aura granted multiple executives with hundreds of thousands of options and RSUs; Akebia issued 8,400 options; Abeona provided up to 13,300 restricted shares across five hires; Faeth distributed 94,000 options across three new employees. All programs are designed to incentivize newly hired leadership and align interests with long-term company performance, with options generally carrying a ten-year term. The companies’ focuses span CXCR4-targeted therapies for rare hematology and immune-related diseases, ocular cancer therapeutics, kidney disease, autologous cell and gene therapies for wounds, and multi-node oncogenic pathway inhibition. These inducement grants reflect a broader trend of using equity-based compensation to attract senior talent in the biotech sector.